Chief Executive Officer Bent Frandsen comments:

"It is with considerable pride that we announce the establishment of our Oncology Scientific Advisory Board, comprised of six renowned scientists whom I am confident will facilitate the development of ES2B-C001 in a manner that optimizes its potential. As ES2B-C001 gains momentum on its progress towards clinical development, ExpreS[2]ion is at a critical juncture in which the OSAB will augment the Company's already deep R&D competencies. On behalf of ExpreS[2]ion, I welcome our new OSAB members to the ExpreS[2]ion story and look forward to developing a therapy that will potentially benefit women suffering from HER2-expressing breast cancer worldwide."

Chief Medical Officer Mattis Flyvholm Ranthe comments:

"This team of experts brings unique and best-in-class specialists together, providing critical input to ExpreS[2]ion's clinical development program of our therapeutic HER2 directed vaccine, allowing it to meet the needs of patients and physicians alike. In a dynamic treatment landscape, input from Key Opinion Leaders is crucial in maximizing the likelihood of success in our efforts to develop a safe and efficacious product. Our pre-clinical data gives us sound reason-to-believe regarding anticancer effects, but equally important is aiming for the right patient populations from the start, and here our experienced Key Opinion Leaders provide expert input. These are world-class leaders in the field of HER2 expressing cancers, and will be able to provide critical input into overall development, trial designs, and patient populations. This is a huge step for ExpreS[2]ion, bringing us close to the critical milestone of getting our vaccine into clinical development, and eventually to the right patients."

The inaugural members of the ExpreS[2]ion's OSAB

Dr. Giuseppe Curigliano, MD, PhD

Dr. Curigliano is an Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, Italy (IRCCS). He is a clinician and researcher specialising in early drug development for patients with solid tumours with a special commitment to breast cancer. Dr. Curigliano is recognized among the leading experts in the world within the field of HER2 expressing breast cancer. He serves the European Society for Medical Oncology (ESMO) as the Chair of the Guidelines Committee and is a Council Member. He was awarded the first European School of Oncology (ESO) Umberto Veronesi Award in Vienna in 2017, and the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. Dr. Curigliano serves as editor on several scientific journals and has authored or co-authored more than 650 peer-reviewed scientific papers and several chapters in oncology textbooks.

Dr. Javier Cortes, MD, PhD

Dr. Cortes is a Doctor in Medical Oncology, and Head of the International Breast Cancer Centre (IBCC) in Barcelona. Since 2006, he has held leading positions within breast cancer research with leading institutions and universities. He is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), and is a member of expert panels that develop the treatment guidelines for metastatic breast cancer. He is the author of more than 380 publications, primarily focused on breast tumours and new drugs, and more than 800 communications at different conferences. He actively participates in the development of numerous international clinical trials.

Dr. Ulrik Lassen, MD, PhD

Dr. Lassen is a Professor at University of Copenhagen, Department of Clinical Medicine. In 2017, he was appointed Head of the Department of Oncology at Copenhagen University Hospital, Rigshospitalet, Denmark. As a Clinical Oncologist he has been working with Phase 1 Oncology trials since 2005 and is ESMO board certified in Medical Oncology. As Professor in Clinical Oncology he has a special focus on personalized medicine. Established the Phase 1 Unit at Rigshospitalet in 2005, and established Copenhagen Prospective Personalized Oncology program (CoPPO) in 2013.  Dr. Lassen is member of, and has held leading positions in Danish Association of Cancer Research and Danish Society of Clinical Oncology. Dr. Lassen has (co-)authored 297 peer reviewed publications.

Dr. Michael Andersson, MD, DMSci 

Dr. Andersson is a Clinical Oncologist working as consultant at the Breast Oncology Unit in the Copenhagen University Hospital, Rigshospitalet, Denmark since 1998. He has special interest in HER2-positive breast cancer and has published on and been Principal Investigator in several national and international studies of HER2-positive early and metastatic breast cancer. Dr. Andersson has authored or co-authored 143 peer reviewed publications.

Dr. Rupert Bartsch, MD

Dr. Bartsch is an Associate Professor of medicine at the Medical University of Vienna in Austria and serves as the director of the Breast Cancer Programme at the Department of Oncology. Prior to joining the Medical University of Vienna, he was Head of the Breast Centre at the Elisabethinen Hospital in Linz, Austria, and was temporarily based at the German Breast Group in Neu Isenburg, Germany. Dr. Bartsch has a longstanding clinical and scientific focus on breast cancer and brain metastases. Together with his colleagues, he has published over 150 articles in peer-reviewed journals, among them Nature Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology and Clinical Cancer Research.

Dr. Daniel Lenihan, MD, FACC, FESC, FIC-OS

Dr. Lenihan has been active in cardio-oncology, for over 25 years. He has previously held positions at MD Anderson Cancer Center in Houston, Texas, Vanderbilt University in Nashville, Tennessee, and Washington University in St Louis, Missouri. Dr. Lenihan is the Founder and Immediate Past President of the International Cardio-Oncology Society (IC-OS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. Dr. Lenihan serves as editor on several scientific journals and has authored or co-authored 216 peer-reviewed scientific papers and authored several books and book chapters on cardio-oncology.